Becton Dickinson and (NYSE:BDX) was upgraded by investment analysts at Citigroup from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Friday.
BDX has been the subject of a number of other research reports. Royal Bank of Canada restated a “hold” rating and set a $210.00 price objective on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research cut shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Deutsche Bank set a $260.00 price target on shares of Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price target on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, Morgan Stanley increased their target price on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $230.20.
Shares of Becton Dickinson and (NYSE BDX) traded up $1.00 during midday trading on Friday, hitting $220.99. 1,332,300 shares of the company’s stock were exchanged, compared to its average volume of 1,923,533. Becton Dickinson and has a one year low of $163.36 and a one year high of $229.68. The company has a market capitalization of $51,010.00, a P/E ratio of 47.52, a PEG ratio of 1.72 and a beta of 1.07. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. Becton Dickinson and’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.12 earnings per share. research analysts expect that Becton Dickinson and will post 10.63 earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. North Star Investment Management Corp. increased its stake in shares of Becton Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after acquiring an additional 18 shares in the last quarter. Crestwood Advisors Group LLC purchased a new position in Becton Dickinson and during the 1st quarter worth $101,000. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson and during the 1st quarter worth $105,000. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in shares of Becton Dickinson and during the 3rd quarter worth $108,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Becton Dickinson and by 0.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 624 shares of the medical instruments supplier’s stock worth $113,000 after purchasing an additional 5 shares during the period. Institutional investors and hedge funds own 87.72% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Becton Dickinson and (BDX) Upgraded by Citigroup to Neutral” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/becton-dickinson-and-bdx-upgraded-by-citigroup-to-neutral.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.